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Abstract CD40L has a well-established role in enhanc-
ing the immunostimulatory capacity of normal and
malignant B cells, but a formulation suitable for clinical
use has not been widely available. Like other TNF family
members, in vivo and in vitro activity of CD40L requires a
homotrimeric conﬁguration, and growing evidence sug-
gests that bioactivity depends on higher-order clustering of
CD40. We generated a novel formulation of human
recombinant CD40L (CD40L-Tri) in which the CD40L
extracellular domain and a trimerization motif are con-
nected by a long ﬂexible peptide linker. We demonstrate
that CD40L-Tri signiﬁcantly expands normal CD19? B
cells by over 20- to 30-fold over 14 days and induces B
cells to become highly immunostimulatory antigen-pre-
senting cells (APCs). Consistent with these results,
CD40L-Tri-activated B cells could effectively stimulate
antigen-speciﬁc T responses (against the inﬂuenza M1
peptide) from normal volunteers. In addition, CD40L-Tri
could induce malignant B cells to become effective APCs,
such that tumor-directed immune responses could be probed.
Together, our studies demonstrate the potent immune-stimu-
latory effects of CD40L-Tri on B cells that enable their
expansion of antigen-speciﬁc human T cells. The potent
bioactivity of CD40L-Tri is related to its ability to self-mul-
timerize, which may be facilitated by its long peptide linker.
Keywords CD40   CD40L   B lymphocytes  
Immunotherapy   Antigen-presenting cell
Introduction
The CD40:CD40Ligand (CD40L) pathway provides
essential signals for T cell help for B cell antibody pro-
duction and dendritic cell priming of CD8? T cell
responses. CD40 is a member of the tumor necrosis factor
receptor (TNFR) superfamily and is a type I transmem-
brane protein that is highly expressed on diverse cell types
including many antigen-presenting cells (APC), such as B
cells, dendritic cells, macrophages, and endothelial cells
[1, 2]. The physiological ligand of CD40 is CD40L (CD154).
Expressed on activated T cells, this type II transmembrane
protein is a member of the TNF family of ligands and
naturally forms a trimer on the cell surface. The interaction
of CD40L with CD40 effectively increases function of
APCs, through the induction of costimulatory molecules as
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DOI 10.1007/s00262-012-1331-4well as inﬂammatory cytokines and chemokines. Numer-
ous reports have demonstrated that APCs that are activated
as a result of the CD40L-CD40 interaction induce T cell
activation [3, 4].
Together, these studies have supported the promise of
CD40L-activated B cells for immunotherapeutic applica-
tions [5]. A widely available murine ﬁbroblast cell line,
engineered to stably express human CD40L (NIH3T3/
tCD40L), has been shown to induce rapid expansion of
normal human CD19? B cells [6, 7]. These studies have
provided proof-of-concept that CD40L-mediated stimula-
tion can feasibly generate a large source of autologous
APCs from relatively small amounts of peripheral blood.
However, the presence of and response to mouse xenoan-
tigens within the 3T3 cell system precludes its further
clinical development. At the same time, despite the highly
attractive immunostimulatory proﬁle of CD40L, a puriﬁed
soluble recombinant human formulation has not been
readily available [8].
We sought to construct a soluble recombinant CD40L
molecule that was sufﬁciently active to expand human B
cells in vitro for use as APCs. A number of soluble recom-
binant forms of CD40L have been described with varying
levels of bioactivity. These include formulations comprised
of solely the TNF homology domain, of the TNF homology
domain with the 75 amino acid stalk that joins the TNF
domain to the membrane, and of each of the above joined to
an isoleucine zipper trimerization motif [9, 10]. In addition,
multimeric formulations of CD40L trimers have been made
by linking CD40L to Acrp30 to produce a 2-trimer, or with
the body of surfactant protein D to produce a 4-trimer pro-
tein [11, 12]. Some of these forms have short peptide linkers
of 2–5 amino acids between the multimerizing motif and the
CD40L. Studies have shown that the isoleucine zipper or the
natural stalk domain do not increase CD40L bioactivity
through trimerization, which is an intrinsic property of the
TNF homology domain, but by stabilizing the structure by
reducing unfolding of the protein [10]. In general, studies
have shown that the greatest bioactivity is seen with stabi-
lized trimers and multimerized trimers [9–12].
Since ﬂexible peptide linkers of approximately 17 amino
acids have been shown to optimally support folding of
independent protein domains [13], we reasoned that
inclusion of a long linker between the trimerization motif
and the CD40L extracellular domain would best support
CD40L bioactivity. We consequently used this approach to
design a novel formulation of CD40L designated as
CD40L-Tri. We demonstrate that CD40L-Tri readily self-
multimerizes in solution and has potent immunostimula-
tory activity. These results lead us to speculate that the
freedom of movement provided by the long peptide linker
facilitates this process of self-multimerization and thereby
enables effective cross-linking of CD40 on the cell surface.
Materials and methods
Patient samples
Heparinized peripheral blood was obtained from normal
adult volunteers and patients enrolled on clinical research
protocols at the Dana-Farber Harvard Cancer Center
(DFHCC) approved by the DFHCC Human Subjects Pro-
tection Committee. Peripheral blood mononuclear cells
(PBMC) were isolated by Ficoll/Hypaque density-gradient
centrifugation and used fresh at the time of the experiment.
Chronic lymphocytic leukemia cells were used fresh or
cryopreserved with 10 % DMSO, and stored in vapor-
phase liquid nitrogen until the time of analysis.
Generation of CD40L-Tri
The CD40L-Tri coding sequence is composed of an opti-
mized IL-2 signal (MRRMQLLLLIALSLALVTNS) [14],
an octahistidine, a trimeric leucine zipper GCN4pII heptad
repeat derived from the wildtype dimeric GCN4 repeat
found in Saccharomyces cerevisiae (GDRMKQIEDKIE
EILSKIYHIENEIARIKKLIGER) [15], a ﬂexible 17 amino
acid linker (TSGGSGGTGGSGGTGGS) [13], and the
extracellular domain of human CD40L (amino acids
51–261) [9]. The coding sequence was codon-optimized for
CHO cell expression and synthesized by Genscript (Piscat-
away, NJ). The calculated molecular weight after signal
cleavage is 30,093 daltons with a pI of 7.63. There is one
predictedN-glycosylationsite,whichisexpectedtoincrease
the molecular weight to the observed 35 kDa (Fig. 1c).
The CD40L-Tri insert was cloned into the pEFGF
expression vector. The pEFGF vector is composed of
4.1 Kb 50 of the hamster EF-1 gene including the EF-1
promoter, ending in a Kozak consensus start site that
includes Nco I, EcoRV, and Sal I sites, followed by 0.5 Kb
encephalomyocarditis (EMC) virus internal ribosome entry
site (IRES) [16, 17], dihydrofolate reductase (DHFR)
cDNA, the 4.3 kb hamster EF-1 polyadenylation and
30 ﬂanking sequence, ampicillin resistance, and origin of
replication. This vector was based on the ﬁnding that non-
promoter genomic elements in the hamster EF-1 locus
support high-level protein expression independent of where
the vector is integrated into the genome [18]. These non-
promoter elements might include insulator elements, scaf-
fold/matrix attachment regions, transcriptional enhancers,
or terminators. The elements of the vector were generated
by high-ﬁdelity PCR with a unique restriction site and
15-bp overlap at the junction of each element, joined by
In-Fusion [19], and conﬁrmed by sequencing. The pEFGF
vector was digested with Nco I and Sal I, and the CD40L-
Tri coding sequence was ampliﬁed from the synthetic
template with primers including 15-bp overlaps to the Nco
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123I and Sal I sites of the vector and joined by In-Fusion.
DHFR-deﬁcient CHO cells (DG44) were electroporated
with Mlu-linearized CD40L-Tri vector. After 2 days in
non-selective media, cells were cultured in MEMa media
without ribonucleosides and deoxyribonucleosides, 10 %
dialyzed fetal bovine serum, 1 % glutamax, penicillin/
streptomycin, and 15 mg/ml gentamicin. After 5 days,
methotrexate was added to 25 nM and culture was con-
tinued until colonies grew out. Colonies were pooled and
the concentration of methotrexate was increased in twofold
steps to 1,000 nM, waiting for robust growth at each stage.
Cells were subcloned at the 50 and 1,000 nM stages and
selected for highest production level by ELISA. Cells were
adapted to low-serum media, and culture supernatant
was concentrated 12-fold by 50 kDa cut-off hollow ﬁber
ultraﬁltration (Spectrum Labs). Concentrated supernatant
was passed through a column of His-Select HF Nickel
Afﬁnity Gel (Sigma), and the column was washed with 10
and 50 mM imidazole in 50 mM phosphate, 300 mM
NaCl, pH 8.0, and eluted with 150 mM imidazole in the
same buffer. The eluate was dialyzed twice against PBS,
pH 7.0, and sterile ﬁltered through 0.22 micron ﬁlter with a
yield of 2.5 mg per liter. Of note, the 50 mM imidazole
wash was necessary to remove a 55 kDa CHO cell protein,
legumain. Endotoxin was determined by LAL gel assay to
be less than 2 EU/mg protein.
Other CD40L formulations
We tested 3 other formulations of human CD40L. Culture
supernatants containing multimeric CD40L (‘Ultra-
CD40L’, kindly provided by Richard Kornbluth, Multi-
meric, Inc, La Jolla, CA, USA) were produced by fusing the
extracellular domain of CD40L with the body of surfactant
protein D (a spontaneously multimerizing molecule)
resulting in a 4-trimer soluble protein. We also tested a
homotrimeric form of soluble human recombinant CD40L
with a short linker, which we designated as ‘shrtCD40L’
(#2706-CL; R&D, Minneapolis, MN, USA). This form is
only robustly active when cross-linked by monoclonal
antibodiesagainsttheamino-terminalepitopetags(HexaHis
or HA). As a positive control, we tested the natural mem-
brane-bound form of human CD40L made by stable trans-
fection of NIH3T3 cells, termed ‘NIH3T3/tCD40L’ [21].
Expansion of human B cells with CD40L
CD19? B cells were isolated from normal PBMC by
immunomagnetic selection (CD19? microbeads, Miltenyi,
Auburn, CA, USA), and seeded at 2 9 10
6 cells/well in a
24-well plate. Alternatively, the B cells were seeded at
0.3 9 10
6cells in 2 ml in a 25 cm
2cell culture ﬂask. Bcells
were cultured in B cell media (Iscove’s modiﬁed Dulbecco
medium (IMDM, Life Technologies)), supplemented with
10 % heat-inactivated human AB serum (Gemini Bioprod-
ucts, West Sacramento, CA, USA), 5 lg/ml insulin (Sigma
Chemical, St Louis, MO, USA), 15 lg/ml gentamicin and
IL-4 (2 ng/ml, R&D Systems, Minneapolis, MN, USA)
supplemented with CD40L-Tri (at 1–10 lg/ml) [12, 20].
CD40L was replenished every 3–4 days. Alternatively,
CD19? B cells were activated and expanded using the
established NIH3T3/tCD40L system, which acts as a
CD40L-expressing irradiated feeder cell line, in media
supplemented with IL-4 (R&D Systems) and cyclosporin A
(Novartis, Basel, Switzerland) as described [6]. B cell
expansionwas measured by counting cells usingtrypan blue
exclusion.
Immunophenotyping and CFSE analysis
CD40L-activated B cells were evaluated using the fol-
lowing ﬂuorophore-conjugated antibodies: CD80 (PE,
Coulter; Fullerton, CA, USA); CD86 and CD83 (PE and
PE-Cy5; BD Biosciences; San Jose, CA, USA); and CD19
Fig. 1 Generation of
CD40L-Tri. Schematic of
a the CD40L-Tri trimer, and of
b the expression vector used to
generate CD40L-Tri. c Non-
reducing (NR) and reducing
(R) SDS-PAGE of puriﬁed
CD40L-Tri
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123(PC7, Beckman Coulter, Brea, CA, USA). B cells
(0.5 9 10
6) were washed twice with PBS and incubated
with antibodies for 15 min at 4 C. The stained cells were
acquired on a FC500 instrument (Beckman Coulter, Brea,
CA, USA). Analysis of immunophenotyping results was
performed using FlowJo software (Tree Star, Inc. Ashland,
OR). The relative expression of surface antigens was
evaluated using the mean ﬂuorescence intensity (MFI). To
exclude the possibility that positive CD19? B cell selec-
tion could by itself activate B cells, we performed CD40L-
Tri expansion and immunophenotyping on negatively
selected CD19? B cells (B isolation Kit II, Miltenyi,
Auburn, CA, USA). No discernable differences in results of
CD40L activation were observed between positively and
negatively selected B cells (Supplemental Figure 1). To
examine cell division induced by CD40L-Tri, we labeled
normal B cells with 5 lM CFSE (Invitrogen) for 10 min at
37 C. 1 9 10
6 of CFSE-labeled B cells were incubated
with 1 lg/ml of CD40L-Tri. Activated B cells were har-
vested, stained with CD19-PC7 mAb, and analyzed for
CFSE dilution by ﬂow cytometry after 4, 7, and 10 days.
T cell proliferation assay
Two days after activation by CD40L-Tri, Ultra CD40L, or
short CD40L, B cells were irradiated (55 Gy) and used as
stimulators (1–5 9 10
4 cells/well) with immunomagneti-
cally selected CD8? or CD4? allogeneic T cells (1 9 10
5
cells/well; selected using CD8? or CD4? microbeads,
Miltenyi Biotec, Auburn, CA, USA) in a ﬁnal volume of
200 ll in 96-well round-bottom plates, at 37 Ci na5%
CO2 humidiﬁed atmosphere. The cells were cultured in
IMDM media supplemented with 10 % human serum,
2 mmol/L L-glutamine, 100 U/ml penicillin, and 100 lg/
ml streptomycin. All co-culture conditions were performed
in triplicate. After 5 days, 1 lCi [
3H] thymidine (Amer-
sham, PerkinElmer, Waltham, MA, USA) was added to
each well. Cells were harvested onto glass ﬁber ﬁlters after
18–20 h, and [
3H] thymidine incorporation was measured
by scintillation counter.
Generation and testing of M1 peptide-speciﬁc CD8? T
cells and CLL-reactive CD8? T cells
CD8? T cells speciﬁc for the inﬂuenza peptide M1
(GILGFVFTL, New England Peptide, Gardner, MA, USA)
were generated from PBMC of HLA-A2? normal volun-
teers. In brief, 2 9 10
6 PBMCs were stimulated weekly
with irradiated M1-pulsed APC (5 9 10
5 T2 cells), or
autologous B cells stimulated with CD40L-Tri (1 lg/ml)
for a total of two stimulations, in the presence of 10 ng/ml
IL-7 (R&D Systems, Minneapolis, MN, USA). In some
experiments, peptide-pulsed autologous dendritic cells
were used as APC and were generated as previously
described [22]. All APCs were pulsed with peptide over
3 h and irradiated at 55 Gy. To detect the expanded M1-
speciﬁc T cells, CD8? T cells from the bulk co-cultures
were immunomagnetically selected (CD8? microbeads,
Miltenyi, Auburn, CA, USA) and tested against a panel of
target cells by ELISPOT assay. ELISPOT assays were
performed as previously described [22]. In brief, target
cells (50,000 cells/well) were co-incubated with 5,000
effectors on ELISPOT plates (Millipore, Billerica, MA,
USA) in triplicate for 24 h. Interferon-c secretion (IFNc)
was detected using capture and detection antibodies as
directed (Mabtech AB, Mariemont, OH), and then subse-
quently imaged and quantiﬁed (ImmunoSpot Series Ana-
lyzer, Cellular Technology, Cleveland, OH). In other
experiments, cryopreserved CLL cells were thawed, acti-
vated with 1 lg/ml CD40L-Tri, irradiated as described
above, and co-cultured with autologous PBMCs. Ten days
following stimulation, CD8? T cells were immunomag-
netically isolated, and tested for reactivity against CD40L-
activated leukemia cells by ELISPOT assay.
Biochemical characterization
To identify the active form of the CD40L-Tri, 400 lgw a s
buffer-exchanged into HEPES-saline (150 mM NaCl,
20 mM HEPES; pH 7.48), and separated by size-exclusion
chromatography on a Superdex 200 HR10/300 analytical
column(*25 mlbedvolume,HEPES-saline runningbuffer)
inline in an A ¨KTAexplorer 10 FPLC system (GE Healthcare
Life Sciences, Piscataway, NJ). Fractions of 0.5 ml were
collected, and analyzed on reducing SDS-PAGE and native
gels by silver staining (Thermo Scientiﬁc, Rockford, IL).
After sterilization by ﬁltration (Spin-X), these fractions were
tested in tissue culture for upregulation of B cell costimula-
tory markers. Protein content, initially evaluated by absor-
bance at 280 nm, was determined using the microBCA assay
(Thermo Scientiﬁc) as the low aromatic residue content of
CD40L-Tri results in a low molar extinction coefﬁcient (for
monomer, e = 14,440 M
-1 cm
-1).
Statistical analysis
A one-sided paired Student’s t-test was used to test for an
increase from baseline for each treatment groups for the
expression of costimulatory molecules and considered
signiﬁcant if p\0.05. For the T cell proliferation experi-
ments, a 2-way ANOVA model was constructed and
included an interaction term for dilution and treatment
effect. Longitudinal models were constructed for repeated
measures of the ratio of cell number to baseline over time
and included an interaction term for treatment group and
time. A compound symmetry covariance structure was
350 Cancer Immunol Immunother (2013) 62:347–357
123used for these models. All p values provided for longitu-
dinal and ANOVA modeling were Bonferroni adjusted and
considered signiﬁcant if\0.05.
Results
Generation of CD40L-Tri
CD40L-Tri was designed as a self-assembling homotrimer
and consists of a signal sequence, octahistidine motif for
puriﬁcation, isoleucine zipper for trimerization, long ﬂex-
ible linker of 17 amino acids, and the extracellular domain
of CD40L (Fig. 1a). CD40L-Tri was produced in CHO
cells (Fig. 1b) and puriﬁed material consisted primarily of
a 35 kDa protein on reducing SDS-PAGE. Non-reducing
gels showed higher molecular weight bands consistent with
dimeric and trimeric forms (Fig. 1c).
Stimulation of B cells by CD40L-Tri upregulates
expression of costimulatory molecules
Many of the immunostimulatory consequences of CD40L
activation of B cells are mediated through its ability to
upregulate expression of costimulatory molecules such as
CD80, CD83, and CD86. To examine the potency of
CD40L-Tri, we measured its ability to enhance expression
of these molecules compared with known formulations of
CD40L, namely the transfected murine ﬁbroblast line
(NIH3T3/tCD40L) and commercially available epitope-
tagged homotrimeric forms that are formulated with a short
linker (designated ‘shrtCD40L’) and that are inactive
unless cross-linked by tag-speciﬁc antibodies. Culture of
normal CD19? B cells with CD40L-Tri (at 2 lg/ml;
n = 3) consistently resulted in expression of CD80, CD83,
and CD86 at 48 h with mean increases of 29-, 24-, and
165-fold, respectively, (p\0.05) which was comparable
to NIH3T3/tCD40L (25-, 22-, and 146-fold, respectively;
p\0.05) (Fig. 2). Seventy-two hours following exposure
to CD40L-Tri (2 lg/ml), the expression of CD80 and
CD86 persisted (mean of 34- and 180-fold) while expres-
sion of CD83 decreased to 13-fold increase from baseline.
No increase in expression of costimulatory molecules was
observed following exposure to shrtCD40L, as expected
without cross-linking.
CD40L-Tri-activated B cells induce proliferation
of allogeneic CD4? and CD8? T cells
Since CD40L-Tri clearly induced expression of costimu-
latory molecules on B cells, we next investigated the
capacity of CD40L-Tri-activated B cells to stimulate pro-
liferation of allogeneic T cells. B cells were activated with
CD40L-Tri or other CD40L formulations (shrt-CD40L,
NIH3T3/tCD40L, Ultra-CD40L), irradiated, and co-cul-
tured at a ratio of 2:1 or 10:1 with allogeneic CD4? or
CD8? T cells. T cell proliferation was measured by [
3H]
thymidine incorporation at 5 days following the initiation
of co-culture. CD40L-Tri-activated B cells (used at
1–2 lg/ml) consistently stimulated proliferation of CD8?
T cells from three normal volunteers (Fig. 3a, right panel).
At a 2:1 ratio, CD8? T cells, when exposed to allogeneic
CD40L-Tri-activated B cells, proliferated 8–11-fold more
than when exposed to non-activated B cells (p\0.05), and
Fig. 2 CD40L-Tri upregulates
expression of costimulatory
molecules on normal B cells.
CD19? B cells isolated from
normal volunteers (n = 3) were
cultured with various
formulations of CD40L,
including CD40L expressed on
transfected cells (irradiated
NIH3T3/tCD40L), a
recombinant homotrimer with a
short linker (shrtCD40L, gray
symbols), and the test
recombinant protein with a long
ﬂexible linker (CD40L-Tri,
black symbols). Cells were
evaluated by ﬂow cytometry for
expression of CD80, CD83, and
CD86 at the indicated times.
The mean MFI and error bars
(±SD = standard deviation) for
each treatment group are shown
at each time point
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123Fig. 3 CD40L-Tri generates
activated B cells that strongly
stimulate expansion of
allogeneic CD8? and CD4?
T cells. CD19? B cells were
cultured without CD40L (‘no
CD40L’) or with various
formulations of CD40L,
including a recombinant
homotrimer with a long ﬂexible
linker (‘CD40L-Tri’), a
recombinant homotrimer with a
short linker (‘shrtCD40L’), a
recombinant 4-trimer form
(‘Ultra CD40L’), or irradiated
NIH3T3/tCD40L. Activated B
cells were harvested after
2 days, irradiated, and co-
cultured with allogeneic CD8?
T cells (a) or CD4? T cells
(b) at the indicated ratios. T cell
proliferation was measured after
5 days. The ﬁgure displays the
mean and error bars (?SD) for
each treatment group from 3
adult volunteers assayed in
triplicate. c Representative
results (of experiments from 3
donors) of generation of M1
peptide-speciﬁc CD8? T cells
from a HLA-A2? donor, by
stimulation of T cells with M1
peptide (10 lg/ml) loaded on
T2 cells, CD40L-Tri-activated
B cells, normal B cells, or DCs.
After 1 week, expanded CD8?
T cells (5,000) were co-cultured
with the indicated target cells
with or without M1 peptide for
24 h on IFNc ELISPOT plates
in triplicate
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1236–8-fold more than when exposed to B cells treated with
shrt-CD40L (1 lg/ml) (p\0.05), which is known to be
non-bioactive in the absence of a cross-linking antibody.
These results compared favorably to the extent of prolif-
eration elicited by NIH3T3/tCD40L-activated B cells
(22-foldmorethannon-activatedBcells;p\0.05).Similarly,
as shown in Fig. 3b (right panel), we observed high pro-
liferation of allogeneic CD4? cells when co-cultured with
irradiated CD40L-Tri-activated B cells at 2:1 ratio (12–13-
fold, compared with either shrt-CD40L or non-activated B
cells) that was comparable to stimulation by NIH3T3/
tCD40L-activated B cells (14-fold). We also established
that the stimulatory capacity of CD40L-Tri-activated B
cells was as strong as B cells activated by a multimerized
CD40L (Ultra-CD40L) [11] (Fig. 3a, b left panel). Toge-
ther, these results demonstrate that CD40L-Tri has potent
immunostimulatory activity.
CD40L-Tri-activated B cells are effective stimulators
and targets of antigen-speciﬁc T cells
We next conﬁrmed that CD40L-Tri could stimulate
expansion of CD8? T cells in an antigen-speciﬁc manner,
using the well-characterized HLA-A2? restricted inﬂuenza
M1 peptide (GILGFVFTL) as immunogen. HLA-A2?
PBMC were stimulated with M1-pulsed autologous
CD40L-Tri B cells, non-activated B cells, dendritic cells,
or the HLA-A2-expressing T2 cell line. Following two
weekly stimulations with the M1 peptide, CD8? T cells
were isolated from the bulk cultures and speciﬁcity for M1
peptide was tested by IFN-c ELISPOT. CD40L-Tri-acti-
vated B cells displayed comparable immunostimulatory
capacity as dendritic cells and were far superior to non-
activated B cells (Fig. 3c). In addition, CD40L-Tri-acti-
vated B cells stimulated T cell expansion with much better
speciﬁcity than T2 cells. Furthermore, peptide-pulsed
CD40L-Tri-activated B cells functioned well as targets of
antigen-speciﬁc T cells (Fig. 3c).
We further tested the capacity of CD40L-Tri to increase
the immunostimulatory activity of malignant B cells.
Chronic lymphocytic leukemia (CLL), a disease of clonal
CD19? CD5? CD23? B cells, is sensitive to immune
modulation. The development of methods to stimulate and
monitor immunity against these leukemia cells, however,
has been impaired by the poor antigen-presenting ability of
CLL cells due to their low expression of costimulatory
molecules. These defects can be reversed through stimu-
lation with CD40L, for example, through use of the widely
used NIH3T3/tCD40L system [23]. We observed that like
normal CD19? B cells, CLL cells (either fresh or cryo-
preserved) gain enhanced expression of costimulatory
molecules following CD40L-Tri exposure (Fig. 4a, Sup-
plemental Figure 2). We therefore tested a series of PBMC
samples collected from CLL patients before and after
allogeneic hematopoietic stem cell transplantation (HSCT)
for the development of anti-CLL immunity after HSCT.
These patients demonstrated molecular remission follow-
ing HSCT. As shown in the example in Fig. 4b, patient
PBMC that were collected 6 months following HSCT were
co-cultured with CD40L-Tri-activated autologous CLL
cells, and then puriﬁed CD8 T cells were restimulated in an
IFNc-ELISPOT assay with autologous CLL cells activated
by CD40L-Tri, NIH3T3/tCD40L, or shrtCD40L, or by
PHA. CD40L activation of CLL cells by the CD40L-
transfected cell line or by CD40L-Tri elicited equivalently
high reactivity, while the shrtCD40L-activated tumor tar-
gets elicited detectable but weaker reactivity. Patient
PBMC collected before HSCT had minimal reactivity.
CD40L-Tri elicits expansion of B cells
The ability of human CD40L to persistently expand normal
B cells has been described [7, 11] and establishes the
potential of using this molecule to generate a renewable
source of antigen-presenting cells from primary human
cells. We initially compared the ability of CD40L-Tri and
NIH3T3/tCD40L cells to induce and sustain proliferation
of B cells in high-density cultures (2 million cells/2 ml
initial seeding density). As expected, we observed a lack of
expansion of CD19? B cells in the presence of IL-4-con-
taining media without CD40L, and a ninefold mean
expansion with NIH3T3/tCD40L cells at day 28 (Fig. 5a).
CD40L-Tri (1, 2, and 10 lg/ml, replenished every
3–4 days) stimulated B cells expanded by 4–5-fold at day
28 compared with IL-4 (0.10-fold) (p\0.05); however,
this was less than the expansion with NIH3T3/tCD40L
cells. These results were not altered by addition of condi-
tioned media from NIH3T3 cells together with CD40L-Tri
into the culture media, excluding the idea that the NIH3T3
cells provided soluble factors that contributed to B cell
proliferation (data not shown).
On the other hand, we observed much more expansion
when B cell cultures were initiated at low density
(0.3 9 10
6 cells/2 ml seeding density) (Fig. 5b). At this
approximately tenfold lower seeding density, CD40L-Tri
(2.0 lg/ml) stimulation resulted in a 20- to 30-fold mean
expansion at 14 days. At day 28, the rate of expansion
decreased to a mean of 18-fold. Notably, analysis of B cell
division by CFSE dilution demonstrated proliferation
within the entire population of B cells (Fig. 5c).
The favorable growth kinetics in low initial B cell
seeding density between the soluble formulations and the
CD40L-expressing murine ﬁbroblast line likely reﬂects the
difference in CD40L bioavailability when provided as
soluble recombinant form or as a continuously renewing
membrane source from a cell line.
Cancer Immunol Immunother (2013) 62:347–357 353
123Bioactivity of CD40L-Tri is related to
self-multimerization
Since we observed that CD40L-Tri bioactivity was similar
to that of a multimerized CD40L, we queried whether
CD40L-Tri was aggregating in solution and which
molecular size fraction exhibited the greatest bioactivity.
Size-exclusion gel chromatography (SEC) revealed that
CD40L-Tri eluted primarily in a single peak (fractions #3
and #4, eluting at 8–9 ml coinciding with the void volume
and slightly after) consistent with a molecular weight range
of *400 kDa and higher. A second smaller peak eluted in
fractions #15–17 (eluting at 14–15.5 ml) and corresponded
to a molecular weight of *65 kDa (Fig. 6a).
We consistently noted across experiments using several
columns that CD40L-Tri exhibits secondary interactions
with the Superdex matrix retarding its elution leading to an
underestimation of the nominal molecular weight. As a
consequence, we ran a native gel in a glycine-based system
(pH 8.8; to ensure that CD40L-Tri was negatively charged).
We observed that the unseparated starting material
appeared as a smear initiating at *90–100 kDa that grad-
ually increased to large aggregates that did not enter the gel
(Fig. 6b, left). On the other hand, reducing gel analysis of
the CD40L-Tri starting material clearly indicated that the
dominant component is the CD40L monomer (Fig. 6b,
right). Furthermore, similar analysis of fractions 4 and 16
indicated they consist of identical components of *35 kDa
in size, consistent with the CD40L monomer. Our results
thus support the conclusion that the majority of the material
in CD40L-Tri is contained in the ﬁrst eluting peak and
consists of higher-order oligomers of the material in the
second eluting peak (which appears to consist of the
CD40L-Tri base trimer).
Comparison of the bioactivity of the unseparated and
fractionated material revealed that pooled fractions 3 and 4
showed a comparable strong stimulatory capacity as the
starting material and that the following chromatographic
Fig. 4 CD40L-Tri-activated CLL cells effectively elicit patient
CD8? T cell responses. a Tumor cells freshly isolated from CLL
patients (n = 4) were directly cultured with CD40L-Tri, irradiated
CD40L-expressing NIH3T3 cells (NIH3T3/tCD40L), or recombinant
CD40L (shrtCD40L) (open bars) or initially cryopreserved, thawed,
and then incubated with the various CD40L formulations (black
bars). Forty-eight hours later, the expression of CD80, CD83, and
CD86 was evaluated by ﬂow cytometry. The mean MFI and error
bars (±SD) for each treatment group are depicted. b PBMCs from a
patient with chronic lymphocytic leukemia (CLL) before hematopoi-
etic allogeneic stem cell transplantation (‘pre-HSCT’) (top) and
following transplant (‘post-HSCT’) (bottom) were stimulated with
CD40L-Tri-activated autologous CLL cells, and immunomagnetically
selected CD8? T cells were restimulated on ELISPOT assay with
autologous CLL cells activated by the indicated CD40L formulation.
The mean number of IFNc-speciﬁc spots is displayed for each group
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123fractions exhibited a gradual decline in biological activity.
Pooled fractions collected from the second eluting peak
(fraction 16 and 17) moderately induce cell surface
expression of CD80 and CD86 in CD19? B cells, sup-
porting the notion that this eluting peak contains single
CD40L-Tri timer. However, the biological activity of the
unseparated CD40L-Tri material is predominantly main-
tained within the ﬁrst eluting peak, suggesting that the
potent immune-stimulatory effects of CD40L-Tri on B
cells are constituted by self-multimerization.
Discussion
It has long been appreciated that CD40L is physiologically
formulated on the cell surface in vivo as a homotrimer.
Growing evidence, however, suggests that homotrimeriza-
tion alone is necessary but not sufﬁcient for maximal
activity [11]. Rather, higher-order clustering of CD40
appears to be required for optimal CD40 signaling. These
concepts have been supported by studies demonstrating that
multimeric forms of CD40L homotrimers were more active
than homotrimers alone [9–12]. More recently, the mech-
anism underlying the activity of agonistic CD40 antibodies
has been elucidated and shown to rely on the clustering of
mAb-FcR units [24]. In the current manuscript, we describe
a novel formulation of a highly active single trimer
recombinant formulation, CD40L-Tri, that is constructed
using a long ﬂexible linker. We have demonstrated that
CD40L-Tri efﬁciently upregulated costimulatory molecules
on B cells, dramatically induced B cell expansion, and that
these activated B cells could stimulate T cell responses.
We found that the high bioactivity of our CD40L-Tri
appears to depend on multimerization of trimers. Gener-
ally, TNFR family members are monomers that interact
with a TNF family member by a single TNFR binding in
Fig. 5 CD40L-Tri can effectively expand normal B cells. Average
fold increase in B cell number, when CD19? B cells were seeded at
a high density (2 9 10
6 CD19? B cells/2 ml) and b low density
(0.3 9 10
6 CD19?/2 ml). B cells were incubated with the indicated
CD40L formulation as described in ‘Materials and methods’, counted
on the indicated days and the ratio of cell number to baseline was
calculated, with each line representing the mean ± SD over time,
obtained from testing of cells from 3 adult volunteers. In (a), the
signiﬁcance is only shown for day 28 based on modeling for each
group versus IL-4 alone, and the trend over all time points was
signiﬁcantly different for each group versus IL-4, p\0.001.
**p\0.001 for each CD40L-Tri group compared with IL-4 alone.
c CFSE-labeled normal B cells were stimulated with CD40L-Tri and
cell division measured by CFSE dilution (shaded) by ﬂow cytometry,
compared with non-activated cells (‘IL4 alone’, non-shaded)
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123each of the 3 interfacial grooves formed by trimerization of
TNF, thus generating a 3:3 complex [25]. Recently, crys-
tallography studies have demonstrated that the co-crystal
structure of CD40:CD40L unexpectedly showed a 2:3
stoichiometry with a CD40 occupying only 2 of the 3
available CD40L grooves [26]. We therefore speculate that
the addition of the long 17 aa linker in the CD40L-Tri
molecule provides an extra degree of freedom that enables
effective CD40 signaling on cell surfaces.
CD40L-Tri is straightforward to manufacture, and could
be readily applied for investigative studies in immuno-
therapy and B cell biology. We demonstrate that CD40L-
Tri-activated B cells can generate autologous APCs with
equivalent potency as dendritic cells, but have the advan-
tage that little starting material is needed. Compared with
the conventionally available NIH3T3/tCD40L cells, using
recombinant CD40L-Tri is far less labor intensive, easier to
control, and eliminates the xenoantigen exposure that can
confound studies of T cell reactivity. We also show that
CD40L-Tri-activated B cells function well as targets of T
cell responses. On the other hand, there is a risk of
expanding Tregs using CD40L [27]; however, we did not
see evidence of this in our M1-peptide experiments that
started with PBMC.
A high priority for the ﬁeld of cancer immunotherapy is
the increased availability of potent immunostimulatory
agents for enabling the clinical development of immune
treatments [8]. CD40 and CD40L (CD154) have been
ranked among the 10 most important immunomodulatory
agents. Because of the ease of manufacture, CD40L-Tri
can be readily applied to the clinical setting, with potential
applications for cancer vaccines, adoptive immunotherapy,
and for the monitoring of immune responses.
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